{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(10)"],"submitter":["Aragona P"],"funding":["SIFI"],"pubmed_abstract":["<h4>Introduction</h4>Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.<h4>Methods</h4>This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported out"],"journal":["Ophthalmology and therapy"],"pagination":["2559-2573"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11408441"],"repository":["biostudies-literature"],"pubmed_title":["Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment."],"pmcid":["PMC11408441"],"pubmed_authors":["Dammino E","Giannaccare G","D'Esposito F","Genovese P","Gagliano C","Postorino EI","Mazzone MG","Aragona P","Civiale C"],"additional_accession":[]},"is_claimable":false,"name":"Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment.","description":"<h4>Introduction</h4>Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.<h4>Methods</h4>This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported out","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-03T22:03:06.764Z","creation":"2025-04-04T02:54:16.401Z"},"accession":"S-EPMC11408441","cross_references":{"pubmed":["39060700"],"doi":["10.1007/s40123-024-01003-z"]}}